• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Laboratoires Servier, Les

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of €4.2 billion in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) into research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, cancer and metabolism, immune-inflammatory and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. *

 

	Start	1954-01-01 established
	Group	Servier (Group)
	Industry	pharmaceutical
	Person	Seta, Jean-Philippe (Servier 2003–201310 CEO joined Servier 1984 LEFT 201310)
	Region	Suresnes
	Country	France
	Street	50 rue Carnot
	City	92284 Suresnes Cedex
	Tel	+33-1-5572-6000
		Address record changed: 2014-11-26
Basic data	Employees	H: 10,001 to 50,00 (2019-06-05)
	Currency	EUR
	Annual sales	4,200,000,000 (turnover, consolidated (2018) 2018-12-31)
		* Document for �About Section�: Yposkesi. (6/5/19). "Press Release: Servier Appoints Yposkesi for Lentiviral Vector GMP-Manufacturing in CAR-T Cell Development Technology". Suresnes & Corbeil-Essonnes.
		Record changed: 2019-11-09

Advertisement

More documents for Servier (Group)

• [1] Yposkesi. (6/5/19). "Press Release: Servier Appoints Yposkesi for Lentiviral Vector GMP-Manufacturing in CAR-T Cell Development Technology". Suresnes & Corbeil-Essonnes....
• [2] OSE Immunotherapeutics S.A.. (2/7/19). "Press Release: OSE Immunotherapeutics and Servier Announce First Option within Global License Agreement Exercised for further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases"....
• [3] Allogene Therapeutics, Inc.. (1/28/19). "Press Release: Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy". South San Francisco, CA & Paris....
• [4] Allogene Therapeutics, Inc.. (12/3/18). "Press Release: Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia". South San Francisco, CA & Paris....
• [5] Allogene Therapeutics, Inc.. (11/1/18). "Press Release: Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting". South San Francisco, CA....
• [6] GeNeuro S.A.. (9/18/18). "Press Release: GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier". Paris & Geneva....
• [7] Allogene Therapeutics, Inc.. (9/6/18). "Press Release: Allogene Therapeutics Completes a $120 Million Private Financing". South San Francisco, CA....
• [8] Servier. (4/16/18). "Press Release: Servier Acquires Shire’s Oncology Business to Gain Direct Commercial Access in the US". Paris....
• [9] GeNeuro S.A.. (12/21/17). "Press Release: GeNeuro To Receive €12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study". Geneva....
• [10] Servier. (12/13/17). "Press Release: Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.